Targeting SARS-CoV-2 receptors as a means for reducing infectivity and improving antiviral and immune response: an algorithm-based method for overcoming resistance to antiviral agents

References

• Omer SB, Malani P, Del Rio C. The COVID-19 pandemic in the US: a clinical Update. JAMA. 2020;323(18):1767–1768.
   Web of Science ®Google Scholar
• Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–273. doi: 10.1038/s41586-020-2012-7
   PubMed Web of Science ®Google Scholar
• Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824–1836.
   Web of Science ®Google Scholar
• Mason S, Devincenzo JP, Toovey S, et al. Comparison of antiviral resistance across acute and chronic viral infections. Antiviral Res. 2018;158:103–112. doi: 10.1016/j.antiviral.2018.07.020
   PubMed Web of Science ®Google Scholar
• Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–481. doi: 10.1016/S2213-2600(20)30079-5
   Web of Science ®Google Scholar
• Li X, Geng M, Peng Y, et al. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal. 2020;10(2):102–108. doi: 10.1016/j.jpha.2020.03.001
   Web of Science ®Google Scholar
• Chu H, Chan CM, Zhang X, et al. Middle East respiratory syndrome coronavirus and bat coronavirus HKU9 both can utilize GRP78 for attachment onto host cells. J Biol Chem. 2018;293:11709–11726. doi: 10.1074/jbc.RA118.001897
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and Is Blocked by a clinically proven protease inhibitor. Cell. 2020;181:271–280. e8. doi: 10.1016/j.cell.2020.02.052
   PubMed Web of Science ®Google Scholar
• Sigrist CJ, Bridge A, Le Mercier P. A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res. 2020;177:104759. doi: 10.1016/j.antiviral.2020.104759
   PubMed Web of Science ®Google Scholar
• Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol. 2020;38:1–9.
   PubMed Web of Science ®Google Scholar
• Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and outcomes of 1591 patients infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574–1581. doi: 10.1001/jama.2020.5394
   Web of Science ®Google Scholar
• Chen Y, Li L. SARS-CoV-2: virus dynamics and host response. Lancet Infect Dis. 2020;20(5):515–516. doi: 10.1016/S1473-3099(20)30235-8
   Web of Science ®Google Scholar
• Rokni M, Ghasemi V, Tavakoli Z. Immune responses and pathogenesis of SARS-CoV-2 during an outbreak in Iran: comparison with SARS and MERS. Rev Med Virol. 2020;30(3):e2107.
   Web of Science ®Google Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):1.
   Web of Science ®Google Scholar
• Grifoni A, Sidney J, Zhang Y, et al. A sequence homology and Bioinformatic approach Can Predict Candidate targets for immune responses to SARS-CoV-2. Cell Host Microbe. 2020;27:671–680. e2. doi: 10.1016/j.chom.2020.03.002
   PubMed Web of Science ®Google Scholar
• Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020;11:1620. doi: 10.1038/s41467-020-15562-9
   PubMed Web of Science ®Google Scholar
• Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock. 2016;46:239–248. doi: 10.1097/SHK.0000000000000633
   PubMed Web of Science ®Google Scholar
• Jia H, Sodhi CP, Yamaguchi Y, et al. Pulmonary epithelial TLR4 activation leads to lung injury in Neonatal Necrotizing Enterocolitis. J Immunol. 2016;197:859–871. doi: 10.4049/jimmunol.1600618
   PubMed Web of Science ®Google Scholar
• Acharya KR, Sturrock ED, Riordan JF, et al. Ace revisited: a new target for structure-based drug design. Nat Rev Drug Discovery. 2003;2:891–902. doi: 10.1038/nrd1227
   PubMed Web of Science ®Google Scholar
• Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87:E1–E9. doi: 10.1161/01.RES.87.5.e1
   PubMed Web of Science ®Google Scholar
• Imai Y, Kuba K, Rao S, et al. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112–116. doi: 10.1038/nature03712
   PubMed Web of Science ®Google Scholar
• Jia HP, Look DC, Shi L, et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005;79:14614–14621. doi: 10.1128/JVI.79.23.14614-14621.2005
   PubMed Web of Science ®Google Scholar
• Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426:450–454. doi: 10.1038/nature02145
   PubMed Web of Science ®Google Scholar
• Kuba K, Imai Y, Rao S, et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875–879. doi: 10.1038/nm1267
   PubMed Web of Science ®Google Scholar
• Xu H, Zhong L, Deng J, et al. High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa. Int J Oral Sci. 2020;12:8. doi: 10.1038/s41368-020-0074-x
   PubMed Web of Science ®Google Scholar
• Lukassen S, Chua RL, Trefzer T, et al. SARS-CoV-2 receptor ACE2 and TMPRSS2 are primarily expressed in bronchial transient secretory cells. EMBO J. 2020;39(10):e105114.
   Web of Science ®Google Scholar
• Zhang H, Penninger JM, Li Y, et al. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46:586–590. doi: 10.1007/s00134-020-05985-9
   PubMed Web of Science ®Google Scholar
• Wong SH, Lui RN, Sung JJ. Covid-19 and the digestive system. J Gastroenterol Hepatol. 2020;35(5):744–748. doi: 10.1111/jgh.15047
   Web of Science ®Google Scholar
• Xu X, Chen P, Wang J, et al. Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission. Sci China Life Sci. 2020;63:457–460. doi: 10.1007/s11427-020-1637-5
   PubMed Web of Science ®Google Scholar
• Tai W, He L, Zhang X, et al. Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020;17(6):613–620. doi: 10.1038/s41423-020-0400-4
   Web of Science ®Google Scholar
• Madjid M, Safavi-Naeini P, Solomon SD, et al. Potential effects of coronaviruses on the cardiovascular system: A Review. JAMA Cardiol. 2020 Mar 27. Online ahead of print.
   PubMed Web of Science ®Google Scholar
• Zheng YY, Ma YT, Zhang JY, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259–260. doi: 10.1038/s41569-020-0360-5
   PubMed Web of Science ®Google Scholar
• Burrell LM, Johnston CI, Tikellis C, et al. ACE2, a new regulator of the renin-angiotensin system. Trends Endocrinol Metab. 2004;15:166–169. doi: 10.1016/j.tem.2004.03.001
   PubMed Web of Science ®Google Scholar
• Qi F, Qian S, Zhang S, et al. Single cell RNA sequencing of 13 human tissues identify cell types and receptors of human coronaviruses. Biochem Biophys Res Commun. 2020;526(1):135–140. doi: 10.1016/j.bbrc.2020.03.044
   Web of Science ®Google Scholar
• Yang P, Gu H, Zhao Z, et al. Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury. Sci Rep. 2014;4:7027. doi: 10.1038/srep07027
   PubMed Web of Science ®Google Scholar
• Zou Z, Yan Y, Shu Y, et al. Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections. Nat Commun. 2014;5:3594. doi: 10.1038/ncomms4594
   PubMed Web of Science ®Google Scholar
• Sodhi CP, Wohlford-Lenane C, Yamaguchi Y, et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg(9) bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol. 2018;314:L17–L31. doi: 10.1152/ajplung.00498.2016
   PubMed Web of Science ®Google Scholar
• Wang X, Khaidakov M, Ding Z, et al. Cross-talk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA. Exp Biol Med (Maywood). 2012;237:1394–1401. doi: 10.1258/ebm.2012.012212
   PubMed Web of Science ®Google Scholar
• Rodrigues Prestes TR, Rocha NP, Miranda AS, et al. The anti-inflammatory potential of ACE2/angiotensin-(1-7)/Mas receptor axis: Evidence from Basic and clinical Research. Curr Drug Targets. 2017;18:1301–1313. doi: 10.2174/1389450117666160727142401
   PubMed Web of Science ®Google Scholar
• Fang F, Liu GC, Zhou X, et al. Loss of ACE2 exacerbates murine renal ischemia-reperfusion injury. PLoS One. 2013;8:e71433. doi: 10.1371/journal.pone.0071433
   PubMed Web of Science ®Google Scholar
• Chen Q, Liu J, Wang W, et al. Sini decoction ameliorates sepsis-induced acute lung injury via regulating ACE2-Ang (1-7)-Mas axis and inhibiting the MAPK signaling pathway. Biomed Pharmacother. 2019;115:108971. doi: 10.1016/j.biopha.2019.108971
   PubMed Web of Science ®Google Scholar
• Jin HY, Song B, Oudit GY, et al. ACE2 deficiency enhances angiotensin II-mediated aortic profilin-1 expression, inflammation and peroxynitrite production. PLoS One. 2012;7:e38502. doi: 10.1371/journal.pone.0038502
   PubMed Web of Science ®Google Scholar
• Meng J, Xiao G, Zhang J, et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. Emerg Microbes Infect. 2020;9:757–760. doi: 10.1080/22221751.2020.1746200
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020;126(12):1671–1681. doi: 10.1161/CIRCRESAHA.120.317134
   Web of Science ®Google Scholar
• Rohrborn D, Wronkowitz N, Eckel J. DPP4 in diabetes. Front Immunol. 2015;6:386. doi: 10.3389/fimmu.2015.00386
   PubMed Web of Science ®Google Scholar
• Meyerholz DK, Lambertz AM, McCray PB. Jr. Dipeptidyl peptidase 4 distribution in the human respiratory tract: Implications for the Middle East respiratory syndrome. Am J Pathol. 2016;186:78–86. doi: 10.1016/j.ajpath.2015.09.014
   PubMed Web of Science ®Google Scholar
• Lu G, Hu Y, Wang Q, et al. Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature. 2013;500:227–231. doi: 10.1038/nature12328
   PubMed Web of Science ®Google Scholar
• Raj VS, Mou H, Smits SL, et al. Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature. 2013;495:251–254. doi: 10.1038/nature12005
   PubMed Web of Science ®Google Scholar
• Vankadari N, Wilce JA. Emerging WuHan (COVID-19) coronavirus: glycan shield and structure prediction of spike glycoprotein and its interaction with human CD26. Emerg Microbes Infect. 2020;9:601–604. doi: 10.1080/22221751.2020.1739565
   PubMed Web of Science ®Google Scholar
• Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565–574. doi: 10.1016/S0140-6736(20)30251-8
   PubMed Web of Science ®Google Scholar
• Lu G, Wang Q, Gao GF. Bat-to-human: spike features determining ‘host jump’ of coronaviruses SARS-CoV, MERS-CoV, and beyond. Trends Microbiol. 2015;23:468–478. doi: 10.1016/j.tim.2015.06.003
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi: 10.1056/NEJMoa2002032
   Web of Science ®Google Scholar
• Seys LJM, Widagdo W, Verhamme FM, et al. DPP4, the Middle East respiratory syndrome coronavirus receptor, is Upregulated in lungs of Smokers and chronic obstructive pulmonary disease patients. Clinical Infectious Diseases: an Official Publication of the Infectious Diseases Society of America. 2018;66:45–53. doi: 10.1093/cid/cix741
   PubMed Web of Science ®Google Scholar
• Klemann C, Wagner L, Stephan M, et al. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185:1–21. doi: 10.1111/cei.12781
   PubMed Web of Science ®Google Scholar
• Hatano R, Ohnuma K, Yamamoto J, et al. CD26-mediated co-stimulation in human CD8(+) T cells provokes effector function via pro-inflammatory cytokine production. Immunology. 2013;138:165–172. doi: 10.1111/imm.12028
   PubMed Web of Science ®Google Scholar
• Kitagawa N, Hamaguchi M, Majima S, et al. Dipeptidyl peptidase-4 inhibitors have adverse effects for the proliferation of human T cells. J Clin Biochem Nutr. 2018;63:106–112. doi: 10.3164/jcbn.17-64
   PubMed Web of Science ®Google Scholar
• Buhling F, Junker U, Reinhold D, et al. Functional role of CD26 on human B lymphocytes. Immunol Lett. 1995;45:47–51. doi: 10.1016/0165-2478(94)00230-O
   PubMed Web of Science ®Google Scholar
• Al-Qahtani AA, Lyroni K, Aznaourova M, et al. Middle East respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARgamma. Oncotarget. 2017;8:9053–9066. doi: 10.18632/oncotarget.14754
   PubMedGoogle Scholar
• Pinheiro MM, Stoppa CL, Valduga CJ, et al. Sitagliptin inhibit human lymphocytes proliferation and Th1/Th17 differentiation in vitro. Eur J Pharm Sci. 2017;100:17–24. doi: 10.1016/j.ejps.2016.12.040
   PubMed Web of Science ®Google Scholar
• Aso Y, Fukushima M, Sagara M, et al. Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes. Diabetes Res Clin Pract. 2015;110:250–256. doi: 10.1016/j.diabres.2015.10.012
   PubMed Web of Science ®Google Scholar
• Nain M, Mukherjee S, Karmakar SP, et al. GRP78 is an important host factor for Japanese Encephalitis virus entry and replication in Mammalian cells. J Virol. 2017;91(6):e02274–16.
   Web of Science ®Google Scholar
• Triantafilou K, Fradelizi D, Wilson K, et al. GRP78, a coreceptor for coxsackievirus A9, interacts with major histocompatibility complex class I molecules which mediate virus internalization. J Virol. 2002;76:633–643. doi: 10.1128/JVI.76.2.633-643.2002
   PubMed Web of Science ®Google Scholar
• Lee AS. Glucose-regulated proteins in cancer: molecular mechanisms and therapeutic potential. Nat Rev Cancer. 2014;14:263–276. doi: 10.1038/nrc3701
   PubMed Web of Science ®Google Scholar
• Ibrahim IM, Abdelmalek DH, Elfiky AA. GRP78: a cell's response to stress. Life Sci. 2019;226:156–163. doi: 10.1016/j.lfs.2019.04.022
   PubMed Web of Science ®Google Scholar
• Zheng NQ, Zheng ZH, Xu HX, et al. Glucose-regulated protein 78 demonstrates antiviral effects but is more suitable for hepatocellular carcinoma prevention in hepatitis B. Virol J. 2017;14:77. doi: 10.1186/s12985-017-0747-z
   PubMed Web of Science ®Google Scholar
• Liao Y, Fung TS, Huang M, et al. Upregulation of CHOP/GADD153 during coronavirus infectious bronchitis virus infection modulates apoptosis by restricting activation of the extracellular signal-regulated kinase pathway. J Virol. 2013;87:8124–8134. doi: 10.1128/JVI.00626-13
   PubMed Web of Science ®Google Scholar
• Tsai YL, Zhang Y, Tseng CC, et al. Characterization and mechanism of stress-induced translocation of 78-kilodalton glucose-regulated protein (GRP78) to the cell surface. J Biol Chem. 2015;290:8049–8064. doi: 10.1074/jbc.M114.618736
   PubMed Web of Science ®Google Scholar
• Chan CP, Siu KL, Chin KT, et al. Modulation of the unfolded protein response by the severe acute respiratory syndrome coronavirus spike protein. J Virol. 2006;80:9279–9287. doi: 10.1128/JVI.00659-06
   PubMed Web of Science ®Google Scholar
• Ibrahim IM, Abdelmalek DH, Elshahat ME, et al. COVID-19 spike-host cell receptor GRP78 binding site prediction. J Infect. 2020;80:554–562. doi: 10.1016/j.jinf.2020.02.026
   PubMed Web of Science ®Google Scholar
• Li T. Diagnosis and clinical management of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: an operational recommendation of Peking Union medical College Hospital (V2.0). Emerg Microbes Infect. 2020;9:582–585. doi: 10.1080/22221751.2020.1735265
   PubMed Web of Science ®Google Scholar
• Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic Tools. Virol Sin. 2020 Mar 3;1–6. Online ahead of print.
   Web of Science ®Google Scholar
• Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of covid-19 - Preliminary Report. N Engl J Med. 2020 May 22. Online ahead of print.
   Web of Science ®Google Scholar
• Ferner RE, Aronson JK. Remdesivir in covid-19. Br Med J. 2020;369:m1610. doi: 10.1136/bmj.m1610
   PubMed Web of Science ®Google Scholar
• Ledford H. Hopes rise for coronavirus drug remdesivir. Nature. 2020 Apr 29. Online ahead of print.
   Google Scholar
• Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395:1569–1578. doi: 10.1016/S0140-6736(20)31022-9
   PubMed Web of Science ®Google Scholar
• Qaseem A, Yost J, Etxeandia-Ikobaltzeta I, et al. Should Clinicians Use chloroquine or Hydroxychloroquine Alone or in Combination With Azithromycin for the Prophylaxis or treatment of COVID-19? Ann Intern Med. 2020 May 13. Online ahead of print.
   Web of Science ®Google Scholar
• Borba MGS, Val FFA, Sampaio VS, et al. Effect of high vs low doses of chloroquine Diphosphate as Adjunctive therapy for patients hospitalized With severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: A Randomized clinical trial. JAMA Network Open. 2020;3:e208857. doi: 10.1001/jamanetworkopen.2020.8857
   PubMed Web of Science ®Google Scholar
• Principi N, Esposito S. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19. Lancet Infect Dis. 2020;S1473-3099(20)30296-6.
   Web of Science ®Google Scholar
• Jakhar D, Kaur I. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nat Med. 2020;26:632. doi: 10.1038/s41591-020-0853-0
   PubMed Web of Science ®Google Scholar
• Yazdany J, Kim AHJ. Use of Hydroxychloroquine and chloroquine during the COVID-19 pandemic: What Every Clinician should Know. Ann Intern Med. 2020;172(11):754–755. doi: 10.7326/M20-1334
   Web of Science ®Google Scholar
• Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0
   PubMed Web of Science ®Google Scholar
• Irwin KK, Renzette N, Kowalik TF, et al. Antiviral drug resistance as an adaptive process. Virus Evol. 2016;2:vew014. doi: 10.1093/ve/vew014
   PubMed Web of Science ®Google Scholar
• Boas LCP V, Campos ML, Berlanda RLA, et al. Antiviral peptides as promising therapeutic drugs. Cell Mol Life Sci. 2019;76:3525–3542. doi: 10.1007/s00018-019-03138-w
   PubMed Web of Science ®Google Scholar
• Mazzon M, Marsh M. Targeting viral entry as a strategy for broad-spectrum antivirals. F1000Res. 2019;8:1628. doi: 10.12688/f1000research.19694.1
   Google Scholar
• Dobrovolny HM, Beauchemin CAA. Modelling the emergence of influenza drug resistance: The roles of surface proteins, the immune response and antiviral mechanisms. PLoS One. 2017;12:e0180582. doi: 10.1371/journal.pone.0180582
   PubMed Web of Science ®Google Scholar
• Gotte M. The distinct contributions of fitness and genetic barrier to the development of antiviral drug resistance. Curr Opin Virol. 2012;2:644–650. doi: 10.1016/j.coviro.2012.08.004
   PubMed Web of Science ®Google Scholar
• Zhou Y, Hou Y, Shen J, et al. Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2. Cell Discov. 2020;6:14. doi: 10.1038/s41421-020-0153-3
   PubMed Web of Science ®Google Scholar
• Ilan Y. Generating randomness: making the most out of disordering a false order into a real one. J Transl Med. 2019;17:49. doi: 10.1186/s12967-019-1798-2
   PubMed Web of Science ®Google Scholar
• El-Haj M, Kanovitch D, Ilan Y. Personalized inherent randomness of the immune system is manifested by an individualized response to immune triggers and immunomodulatory therapies: a novel platform for designing personalized immunotherapies. Immunol Res. 2019;67:337–347. doi: 10.1007/s12026-019-09101-y
   PubMed Web of Science ®Google Scholar
• Elgart V, Lin JR, Loscalzo J. Determinants of drug-target interactions at the single cell level. PLoS Comput Biol. 2018;14:e1006601. doi: 10.1371/journal.pcbi.1006601
   PubMed Web of Science ®Google Scholar
• Contin M, Alberghini L, Candela C, et al. Intrapatient variation in antiepileptic drug plasma concentration after generic substitution vs stable brand-name drug regimens. Epilepsy Res. 2016;122:79–83. doi: 10.1016/j.eplepsyres.2016.02.012
   PubMed Web of Science ®Google Scholar
• Kenig A, Ilan Y. A personalized Signature and chronotherapy-based platform for improving the efficacy of sepsis treatment. Front Physiol. 2019;10:1542. doi: 10.3389/fphys.2019.01542
   PubMed Web of Science ®Google Scholar
• Khoury T, Ilan Y. Introducing patterns of variability for overcoming compensatory adaptation of the immune system to immunomodulatory agents: a novel method for improving clinical response to anti-TNF therapies. Front Immunol. 2019;10:2726. doi: 10.3389/fimmu.2019.02726
   PubMed Web of Science ®Google Scholar
• Strik AS, Berends SE, Mould DR, et al. Dashboard driven vs. conventional dosing of infliximab in inflammatory bowel disease patients: the PRECISION trial. Journal of Crohn's and Colitis. 2019;13:S063. (Abstract). doi: 10.1093/ecco-jcc/jjy222.090
   Web of Science ®Google Scholar